Animal experiments demonstrate that secondary bile acids inhibit the NLRP3-mediated inflammatory vesicle in macrophages through the activation of TGR5 receptors and thereby ameliorate metabolic syndrome (Di Giorgio et al., 2025). Here, NLRP3 is linked to metabolic syndrome.